KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Inventory (2016 - 2025)

Historic Inventory for Regeneron Pharmaceuticals (REGN) over the last 14 years, with Q4 2025 value amounting to $3.2 billion.

  • Regeneron Pharmaceuticals' Inventory rose 367.64% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year increase of 367.64%. This contributed to the annual value of $3.2 billion for FY2025, which is 367.64% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Inventory stood at $3.2 billion for Q4 2025, which was up 367.64% from $3.3 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Inventory high stood at $3.3 billion for Q3 2025, and its period low was $2.0 billion during Q4 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Inventory had a median value of $2.5 billion in 2023 and averaged $2.6 billion.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 4617.46% in 2021, then plummeted by 800.11% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Inventory stood at $2.0 billion in 2021, then increased by 23.09% to $2.4 billion in 2022, then grew by 7.44% to $2.6 billion in 2023, then increased by 19.64% to $3.1 billion in 2024, then rose by 3.68% to $3.2 billion in 2025.
  • Its last three reported values are $3.2 billion in Q4 2025, $3.3 billion for Q3 2025, and $3.2 billion during Q2 2025.